ArticleBMC cardiovascular disorders2025
Investigation of the characteristics of LDLR gene rs688 polymorphism and its association with dyslipidemia in patients at high to very high cardiovascular risk.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association of LDLR and SCARB1 gene polymorphisms with hepatocellular carcinoma: a case-control study proposing a 'double-hit' model.Lipids in health and disease · 2026Article
- Association of the rs688 Polymorphism in the Gene Encoding Low-Density Lipoprotein Receptor in Bangladeshi Population With Coronary Artery Disease.Genetics research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe rs688 polymorphism in the LDLR gene has been linked to lipid profile alterations, yet its impact in patients at high to very high cardiovascular risk remains unclear.
objectivesTo investigate the association between the LDLR rs688 polymorphism and dyslipidemia in high to very high cardiovascular risk patients.
methodsThis cross-sectional study included patients classified as high or very high cardiovascular risk and matched controls at Can Tho University of Medicine and Pharmacy Hospital. Blood lipid profiles and LDLR rs688 genotyping were assessed using Realtime-PCR.
resultsAmong 80 patients (mean age 62.36 ± 10.49 years; 35.0% male), CT and TT genotypes were more frequent compared to controls (37.5% vs. 30.6%, and 15.0% vs. 3.8%, respectively). The T allele was also more prevalent (33.8% vs. 19.1%). Dyslipidemia was present in 68.8% of patients. T allele carriers had higher dyslipidemia rates (90.7% vs. 57.5%), higher LDLc (5.42 ± 1.51 mmol/L vs. 3.19 ± 1.37 mmol/L), and lower HDLc (0.70 ± 0.25 mmol/L vs. 1.03 ± 0.32 mmol/L) compared to C allele carriers. Multivariate analysis identified the T allele (OR = 14.18) and diabetes mellitus (OR = 4.85) as independent predictors of dyslipidemia.
conclusionThe LDLR rs688 T allele and diabetes mellitus independently increases dyslipidemia risk among patients at high to very high cardiovascular risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.